A POLYPILL INTERVENTION TO IMPROVE ADHERENCE FOR SECONDARY CARDIOVASCULAR DISEASE PREVENTION IN SPAIN: A COST-EFFECTIVENESS STUDY

被引：4
|
作者：
Arrabal, N. [1 ]
Kaskens, L. [1 ]
Garcia-Alonso, F. [1 ]
Gracia, A. [1 ]
机构：
[1] Ferrer Int, Barcelona, Spain
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.883
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV114
引用
收藏
页码：A393 / A393
页数：1
相关论文
共 50 条
  • [41] Maximising the effectiveness and cost-effectiveness of cardiovascular disease prevention in the general population
    Tonkin, Andrew M.
    Boyden, Andrew N.
    Colagiuri, Stephen
    MEDICAL JOURNAL OF AUSTRALIA, 2009, 191 (06) : 300 - 302
  • [42] The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study
    Marshall, Tom
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2006, 13 (04): : 523 - 528
  • [43] Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK
    Michaeli, D. T.
    Michaeli, J. C.
    Boch, T.
    Michaeli, T.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2845 - 2845
  • [44] COST-EFFECTIVENESS OF STATINS, EZETIMIBE AND PCSK9 INHIBITOR FOR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE
    Xiang, Y.
    Du, H.
    Gan, L.
    Li, S.
    Hu, M.
    VALUE IN HEALTH, 2022, 25 (07) : S408 - S408
  • [45] Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis
    Tolla, Mieraf Taddesse
    Norheim, Ole Frithjof
    Memirie, Solomon Tessema
    Abdisa, Senbeta Guteta
    Ababulgu, Awel
    Jerene, Degu
    Bertram, Melanie
    Strand, Kirsten
    Verguet, Stephane
    Johansson, Kjell Arne
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2016, 14
  • [46] Cost-effectiveness of cardiovascular disease prevention and management in the developing world
    Alexandra King
    Nature Reviews Cardiology, 2012, 9 (5) : 258 - 258
  • [47] Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis
    Mieraf Taddesse Tolla
    Ole Frithjof Norheim
    Solomon Tessema Memirie
    Senbeta Guteta Abdisa
    Awel Ababulgu
    Degu Jerene
    Melanie Bertram
    Kirsten Strand
    Stéphane Verguet
    Kjell Arne Johansson
    Cost Effectiveness and Resource Allocation, 14
  • [48] Pravastatin cost-effectiveness for primary prevention of cardiovascular disease in the US
    Hay, JW
    Yuan, Y
    Ford, I
    McGuire, A
    Shepherd, J
    CIRCULATION, 1997, 96 (08) : 1017 - 1017
  • [49] COST-EFFECTIVENESS OF INCREASING STATIN ADHERENCE FOR PRIMARY AND SECONDARY PREVENTION IN COMMUNITY PHARMACIES
    Vegter, S.
    Oosterhof, P.
    van Boven, J. F.
    Stuurman-Bieze, A. G. G.
    Hiddink, E. G.
    Postma, M. J.
    VALUE IN HEALTH, 2013, 16 (07) : A528 - A528
  • [50] Cost-effectiveness of Pravastatin in secondary prevention of coronary artery disease
    Ashraf, T
    Hay, JW
    Pitt, B
    Wittels, E
    Crouse, J
    Davidson, M
    Furberg, CD
    Radican, L
    AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (04): : 409 - 414
12345